(905) 271 2709 mail@focalpointresearch.net
Focal Point
  • Home
  • About
  • Team
  • Services
    • Cosmetic Consultants
    • Natural Health Products
    • Drugs
    • Medical Devices
    • Consumer Products
    • Technology
    • FDA Consulting
    • Health Canada Consultants
    • Regulatory Affairs
    • Pharmacovigilance Services
  • Innovation
  • Articles
  • Contact
Select Page

Revised In-Commerce List (R-ICL) Update

by Jennifer P | Apr 11, 2019 | Canadian Regulatory, Cosmetics, Natural Health Products, OTC Drugs

What is the R-ICL? The Canadian Environmental Protection Act, 1999 (CEPA, 1999) was implemented by Health Canada to protect the environment and human health by contributing towards sustainable development. A section of the Act focuses on decreasing the risks...

It’s Kinda A Big Dill: The Basics of Food Regulation in Canada

by Jennifer P | Dec 20, 2018 | Uncategorized

An essential part of any day, food is all around us.  Accessible from a variety of sources, everywhere from grocery stores to department stores to speciality retailers, if a threat arises, the risk posed to consumers can be grave. Seemingly simple mistakes such...

Reducing Regulatory Burden: Repeal of the Toxics Reduction Act

by Jennifer P | Dec 20, 2018 | Uncategorized

An ongoing process for the Ontario government, goals have been made to reduce the “regulatory burden” on both manufacturers and government. Out with the old and in with the new, the government is looking to clean house of regulations that overlap and add seemingly...

In with the New Out with the Old: Acne Therapy and other Monographs Under Review

by Jennifer P | Dec 5, 2018 | Canadian Regulatory, Natural Health Products, OTC Drugs

When developing a product that requires market authorization, either by way of a DIN (drug identification number) or an NPN (natural product number), product monographs are essential documents provided by Health Canada that layout mandatory label information. These...

Left Out in the Cold: CBD as a Drug alongside Recreational Cannabis Legalization

by Jennifer P | Nov 28, 2018 | Canadian Regulatory, Natural Health Products

The cousin of the cannabinoid family that sits alone in the corner, cannabidiol (CBD) is a relatively silent member in the recreational cannabis legalization family. The non-psychoactive counterpart to THC, this compound had a much lower profile until recently. Before...
« Older Entries

Recent Posts

  • European Commission Adopts Major Changes to Titanium Dioxide Classification
  • Everything You Need To Know About Animal Testing Bans: Where They Stand And Where They Are Headed
  • Feeling Blue: Can Blue Light Damage Your Skin?
  • EPA’s Proposed Prioritization of Chemical Substances
  • 503A Bulks List Prepares for Five Potential New Additions

Recent Comments

    Archives

    • November 2019
    • October 2019
    • September 2019
    • August 2019
    • July 2019
    • May 2019
    • April 2019
    • March 2019
    • February 2019
    • January 2019
    • December 2018
    • November 2018
    • October 2018
    • September 2018
    • August 2018
    • July 2018
    • June 2018
    • May 2018
    • April 2018
    • March 2018
    • February 2018
    • January 2018

    Categories

    • Canadian Regulatory
    • Cosmetics
    • European Regulatory
    • Events/Company Updates
    • Medical Devices
    • Natural Health Products
    • OTC Drugs
    • Our View
    • Research/Science/Technology
    • U.S. Regulatory
    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    Copyright © 2019 Focal Point Research Inc.
    Privacy Policy | Terms of Use
    Website Design and Development by PLAY

    Delsie Braganza

    Delsie joined the Focal Point Research team in 2011 and has been an invaluable asset for our clients. With her strong regulatory and quality assurance background, she is able to audit facilities, set up and maintain GMP compliant facilities, develop strong quality management systems, and co-ordinate successful Health Canada inspections. In addition to this, Delsie oversees all submissions made to Health Canada and the US FDA.

    Delsie obtained an Honours Bachelor of Science (Hons. B. Sc.) in Pharmaceutical Chemistry from the University of Toronto, Post-Graduate Certificate in Pharmaceutical Regulatory Affairs and Quality Operations (RAQ) from Seneca College and Regulatory Affairs Certification (RAC) from the Regulatory Affairs Professional Society (RAPS). When she’s not learning something new, Delsie loves spending time with family, going on road trips or long walks, and swimming.

     


    Jennifer Porter

    Since joining the FPR team in 2011, Jennifer has become our VP/GM managing all staff and projects in the corporate portfolio. She is responsible for finance, accounting and all aspects of IT.

    Jennifer obtained an MBA from University of Redlands, located in Southern California and a B.A. in Psychology from Hawaii Pacific University. When not supporting the needs for her clients, Jennifer enjoys golfing, live music, and traveling.